Treatment of Orthostatic Intolerance

• Status: Active, not recruiting
• Trial end date: 2025-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This trial is designed to study the effects of various mechanistically unique medications in controlling excessive increases in heart rate with standing and in improving the symptoms of orthostatic intolerance in patients with this disorder.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Satish R. Raj
• Collaborator: National Institutes of Health (NIH)
• Treatments: Acetazolamide; Armodafinil; Atomoxetine Hydrochloride; Clonidine; Entacapone; Indomethacin; Isosorbide; Isosorbide Dinitrate; Isosorbide-5-mononitrate; Mecamylamine; Melatonin; Memantine; Midodrine; Modafinil; Octreotide; Propranolol; Sertraline

Criteria

Inclusion Criteria:

• Chronic symptoms (> 6 months) with standing upright

Exclusion Criteria:

• Obvious cause of hypovolemia or drugs that could worsen tachycardia

• Chronic severe medical conditions such as cancer or ischemic heart disease